PPP1CA and hepatocellular carcinoma: Clinical studies indicate that the combination of Lenvatinib and ICIs therapy improves OS and progression‐free survival (PFS) in advanced HCC patients, demonstrating superior efficacy and fewer side effects compared to monotherapy.[33] The combination of Lenvatinib and ICIs therefore represents a promising avenue.[26] We further demonstrated that targeting PP1A enhanced the therapeutic efficacy of Lenvatinib plus ICIs therapy in vivo.